Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations (Q46694321)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations |
scientific article |
Statements
1 reference
Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations (English)
1 reference
Ludovic Lacroix
1 reference
Patricia Pautier
1 reference
Pierre Duvillard
1 reference
Nelly Motté
1 reference
Patrick Saulnier
1 reference
Jean-Michel Bidart
1 reference
1 February 2006
1 reference
118
1 reference
4
1 reference
1068-1069
1 reference
1 reference
Identifiers
1 reference
1 reference